UnitedHealthcare specialty drug prior authorization — care coordinator playbook

End-to-end PA workflow

UHC specialty drug prior authorization is a four-phase workflow for the PCC: benefits investigation through the UHCProvider.com Eligibility and Benefits module, hub program enrollment for benefits investigation support and copay or bridge-supply assistance, PA submission through the correct portal (medical vs pharmacy vs specialty pharmacy referral), and reauth tracking. Where billers most often trip is the OptumRx vs Optum Specialty Pharmacy distinction, the site-of-care steerage gate for HOPD administration, and missing biosimilar step-through documentation on first-line PAs.

Where the UHC workflow breaks

Three failure patterns drive the bulk of stalled UHC specialty PAs:

1. Wrong portal. A medical-benefit drug submitted to OptumRx (or a pharmacy-benefit drug submitted to UHCProvider.com PAAN) gets bounced silently or routed into a queue with a different criteria set, costing days.
2. Missing biosimilar step-through. UHC's 2024-2026 biosimilar policy requires documented intolerance, immunogenicity, or failure on the preferred biosimilar before approving the reference product for bevacizumab, infliximab, rituximab, trastuzumab, pegfilgrastim, and (most recently) adalimumab via the Cordavis arrangement.
3. Site-of-care HOPD denial. The Outpatient Hospital Site of Care Review program denies HOPD administration of many high-cost specialty biologics unless the medical necessity for HOPD is documented (clinical instability, prior infusion reaction, specific monitoring requirements). A site-of-care exception form is the documented pathway for override.

Provider portals

UHC's specialty drug ecosystem spans at least four distinct provider-facing portals, and the choice of portal is determined by the benefit channel and the dispensing model. Submitting to the wrong portal is the most common operational failure on UHC PAs.

PA fax numbers by drug class

The most reliable workflow is to download the drug-specific PA form fresh from UHCProvider.com each time, since the form itself prints the current submission fax at the top.

Peer-to-peer (P2P) review requests

Peer-to-peer review is UHC’s pre-appeal pathway for the prescribing physician to discuss a denied or pended PA with the reviewing medical director. P2P is usually faster than a written Level 1 appeal and can resolve denials based on missing or misinterpreted clinical context.

P2P request workflow

1. Read the denial letter. The denial letter lists the P2P scheduling phone number and the window in which a P2P can be requested (commonly 5-10 business days from the denial date for pre-service denials). Verify the line of business — commercial, MA, and Community Plan each use different P2P queues.
2. Call the P2P scheduling line. Have the member ID, denial reference number, prescribing physician name and direct callback number, and physician’s available windows over the next 3 business days. UHC will schedule a 15-minute call window (often 24-72 hours out).
3. Confirm in writing. Document the scheduled time, the queue (commercial / MA / CP), the reviewer specialty if disclosed, and the reference number.
4. Prep the prescriber. Hand off the documentation packet (below) at least 4 hours before the call so the prescriber walks in cold-prepared, not improvising.
5. Document the call. Capture who from UHC participated (name and credential), the decision (approve, uphold, downgrade), reference number, and any commitments around resubmission with additional information.

Pre-call documentation checklist

• The original PA submission package (CoverMyMeds export or PDF).
• The denial letter with the stated denial reason and the cited UHC medical or pharmacy policy reference.
• The most recent clinical note (within the last 30-60 days) supporting the indication.
• Prior therapy list with dates, doses, duration, and documented response or intolerance.
• Compendia citation supporting any off-label use (NCCN Category 1 or 2A, DrugDex Cat I or IIa, AHFS).
• Laboratory or imaging evidence supporting the indication (e.g., HER2 IHC/FISH for HER2-targeted therapy, EGFR mutation for EGFR-targeted therapy).
• If site-of-care is the issue: the SUPREME Medical Necessity exception form and the clinical rationale for HOPD administration.

Suggested prescriber talking points

Site-of-care policy

UHC’s Outpatient Hospital Site of Care Review program (sometimes called Site of Service or SoS) is the most aggressive site-of-care steerage program among the four major commercial payers in 2026. The program denies HOPD administration of designated high-cost specialty drugs in favor of office-based infusion centers, ambulatory infusion suites, or home infusion when the patient is clinically stable enough for those settings. The drug PA and the site-of-care PA are separate reviews on the same submission and either can fail independently.

Site-of-care exception workflow

When HOPD administration is medically necessary, the exception pathway uses the UHC SUPREME Medical Necessity Form (or the current equivalent listed in the site-of-care medical policy). The form documents: the clinical reason HOPD is necessary (prior Grade 3+ infusion reaction with intervention, hemodynamic instability, concurrent comorbidity requiring HOPD-level monitoring, complex pediatric or geriatric situation), the failed or contraindicated alternative sites, the prescribing physician’s attestation, and the planned administration protocol. Submit through UHCProvider.com PAAN with the drug PA. Site-of-care exceptions are typically decided within the same TAT as the drug PA.

Biosimilar mandate policy

UHC has been the most aggressive of the four major commercial payers on biosimilar substitution since 2022, with policy expanding meaningfully in 2024 and 2025 around adalimumab via the Cordavis private-label arrangement. The policy applies to new starts almost universally and increasingly to continuing patients on reference product without documented clinical reason to stay on reference.

Biosimilar exception criteria

UHC will consider an exception to the biosimilar mandate when the prescriber documents one of: a prior trial of the preferred biosimilar with documented intolerance or AE; documented immunogenicity (anti-drug antibody formation) on the biosimilar; loss of clinical response on the biosimilar after switch; or a clinical situation where switching from reference to biosimilar carries documented risk (rare immunogenicity concerns in stable maintenance patients with specific clinical histories). The exception submission should include the prior therapy timeline, the AE or immunogenicity documentation, and the prescriber’s clinical rationale. The Cordavis adalimumab arrangement has its own exception pathway documented in UHC’s 2024+ specialty drug policy bulletins.

Specialty pharmacy network

UHC’s in-network specialty pharmacy ecosystem is anchored by Optum Specialty Pharmacy, the captive specialty pharmacy under the Optum umbrella (sibling to OptumRx). For most pharmacy-benefit specialty drugs, Optum Specialty is the default and frequently the only in-network specialty pharmacy under the member’s plan. A limited set of additional specialty pharmacies remain in-network for specific drug classes or specific manufacturer-mandated dispensing arrangements (e.g., REMS-restricted distribution).

White-bagging vs brown-bagging vs buy-and-bill

White-bagging (the specialty pharmacy dispenses the drug and ships it directly to the site of care, where it is administered) is UHC’s preferred fulfillment model for designated specialty drugs and is mandatory for drugs on the UHC Specialty Drug Mandate List. The dispensing fee, drug cost, and shipping route through the pharmacy benefit (OptumRx + Optum Specialty), not through the practice’s buy-and-bill billing.

Brown-bagging (the specialty pharmacy ships the drug to the patient, who brings it to the site of care) is generally not permitted by UHC for parenteral specialty drugs due to chain-of-custody and stability concerns.

Buy-and-bill (the practice purchases the drug, administers it, and bills the medical benefit for both the drug and the administration) remains the default for most chemotherapy and many oncology biologics administered in HOPD or community oncology settings, and for specialty drugs not on the white-bag mandate. Verify the current sourcing requirement for each drug before ordering inventory — a buy-and-bill claim for a drug on the white-bag mandate will be denied.

Step therapy requirements

UHC enforces step therapy across the major specialty therapeutic areas. The most-mandated step-throughs in 2026:

Step therapy exception language

UHC will consider a step therapy exception when the prescriber documents one of: intolerance (with specific AE description and date), contraindication (with ICD-10 code or clinical reason), failure (with specific clinical metric and treatment duration), or prior payer step-through grandfathering (the patient previously completed the step-through under a prior payer and continued response on the requested agent). Exception submissions should include the prior therapy timeline with dates, doses, durations, and documented outcome, plus the prescribing physician’s clinical rationale.

Common denials and how to fix them

Appeals process

UHC’s appeals structure has three levels for commercial pre-service appeals: Level 1 internal appeal (filed in writing within the timeframe stated in the denial letter, typically 180 days for commercial; TAT 30 days for pre-service); Level 2 internal appeal (filed if Level 1 upholds; TAT 30 days for pre-service); and external review by an Independent Review Organization (IRO) (filed if Level 2 upholds; TAT typically 45 days standard, 72 hours expedited). For Medicare Advantage, the structure is Plan Reconsideration → Independent Review Entity (IRE, Maximus or C2C) → ALJ → Medicare Appeals Council → Federal Court, with CMS-mandated TATs at each level. Always read the denial letter carefully for the deadline to file each level — missing the window forfeits the appeal right.

Reauthorization intervals

Reauth workflow

Calendar the reauth date 45-60 days before expiration. Refresh the clinical packet with: the most recent clinical note (within 30-60 days), current labs or imaging required by the drug class, current dose record showing on-label compliance, and any new diagnosis information. Submit the reauth through the same portal used for the original PA. If the reauth packet is submitted late and approval lapses, document any therapy continuation gap and prepare a justification for therapy continuation pending re-approval. UHC’s grace policy for in-progress reauth varies by line of business and is not guaranteed.

Frequently asked questions

Which UHC portal do I use to submit a specialty drug prior authorization?

It depends on how the drug is dispensed. For buy-and-bill medical-benefit drugs administered at an HOPD, infusion center, or office, submit through UHCProvider.com under Prior Authorization and Notification (PAAN). For pharmacy-benefit specialty drugs routed through OptumRx, submit via the OptumRx Provider Portal at professionals.optumrx.com (or CoverMyMeds). For drugs dispensed by Optum Specialty Pharmacy under a white-bag arrangement, the referral and PA flow through the Optum Specialty Pharmacy provider portal. Using the wrong portal is the single most common cause of stalled UHC specialty PAs.

What is the difference between OptumRx and Optum Specialty Pharmacy?

OptumRx is the pharmacy benefit manager (PBM) that administers UHC’s pharmacy benefit, manages the formulary, and performs PA review for pharmacy-benefit specialty drugs. Optum Specialty Pharmacy is the dispensing specialty pharmacy operated under the Optum umbrella. They share a parent (UnitedHealth Group / Optum) but operate as separate entities with separate portals, separate PA processes, and separate reps. A UHC PA can route through OptumRx for criteria review while the actual product is dispensed by Optum Specialty Pharmacy under a white-bag arrangement.

Does UHC require biosimilar step-through for Avastin, Herceptin, Remicade, and Rituxan?

Yes. UHC has been among the most aggressive commercial payers on biosimilar substitution. For new starts (and increasingly for continuing patients without documented intolerance), UHC’s specialty drug management policy requires use of a preferred biosimilar before the reference product for bevacizumab (Mvasi, Zirabev, Alymsys, Vegzelma), trastuzumab (multiple biosimilars), infliximab (Inflectra, Renflexis, Avsola), rituximab (Truxima, Ruxience, Riabni), and pegfilgrastim (Fulphila, Udenyca, Ziextenzo, Nyvepria). UHC has also extended biosimilar policy to adalimumab (Humira), with private-label coordination through Cordavis.

How aggressive is UHC site-of-care steerage in 2026?

Very. Since 2023, UHC has expanded its Outpatient Hospital Site of Care Review program to require prior authorization (and frequently to deny) HOPD administration of high-cost specialty drugs that can be administered safely in office-based infusion or home infusion settings. Drugs commonly targeted include infliximab, rituximab, ocrelizumab, IVIG, vedolizumab, and burosumab. The PA criteria require specific documentation of medical necessity for the HOPD setting — clinical instability, monitoring requirements, prior infusion reactions, or other site-specific factors. The SUPREME Medical Necessity exception form is the documented pathway for HOPD overrides.

What is the UHC specialty pharmacy PA turnaround time?

Standard PA review TAT is typically 14 calendar days under commercial plans and 72 hours for urgent requests; Medicare Advantage standard PA TAT is 14 calendar days and 72 hours for expedited. In practice, OptumRx pharmacy-benefit PA decisions on common specialty biologics often return within 24-72 hours when all required clinical documentation is present at submission. Missing biosimilar step-through documentation, missing diagnosis-specific labs, or missing prior therapy records will extend the review window and trigger a request-for-information.

How do I request a UHC peer-to-peer review after a denial?

Peer-to-peer review is requested through the denial letter’s listed P2P scheduling line (number varies by line of business and plan; verify on the denial). Most P2Ps must be requested within a stated window (commonly 5-10 business days from the denial date for pre-service denials). The prescribing physician must conduct the P2P personally; advanced practice providers are generally not accepted on the call. Prep the prescriber with the original PA package, the denial letter and stated reason, the most recent clinical note, prior therapy documentation, and any compendia citation (NCCN, DrugDex Cat I/IIa) supporting the request.

Does UHC require white-bagging for specialty drugs, or is buy-and-bill still allowed?

Both still exist for UHC commercial membership, but the trend is toward white-bagging through Optum Specialty Pharmacy for self-administered injectables and increasingly for office-administered biologics. Buy-and-bill remains the default for chemotherapy and many oncology biologics administered in HOPD or community oncology settings. For specific drugs on the UHC Specialty Drug Mandate List, the payer requires sourcing through a designated specialty pharmacy and will deny buy-and-bill claims. Always verify the current sourcing requirement for the specific drug and plan before ordering inventory.

How do UHC Community Plan (Medicaid) and UHC Medicare Advantage PA criteria differ from commercial?

Each line of business maintains a separate medical and pharmacy policy set. UHC Community Plan (the Medicaid managed-care book) follows state-specific Medicaid formulary and PA criteria layered on top of UHC’s base medical policy, with state-by-state variation in step therapy and prior authorization. UHC Medicare Advantage follows CMS Part B and Part D coverage rules with UHC’s additional medical-necessity criteria for non-formulary requests and step edits. PA forms and submission portals are similar to commercial (UHCProvider.com / OptumRx), but always confirm the criteria set against the member’s specific plan ID before submission — the same drug can have very different PA criteria across UHC’s three books.

Sources

• UnitedHealthcare Provider Portal — Prior Authorization and Notification (PAAN) reference documentation, current calendar year. Accessible at uhcprovider.com (provider login required for criteria documents). Paraphrased.
• OptumRx Provider Portal — Specialty PA criteria, formulary, and Specialty Drug List, current calendar year. Accessible at professionals.optumrx.com.
• UnitedHealthcare Medical Policy Bulletins — site-of-care, biosimilar substitution, specialty drug management, white-bagging mandate. Published on UHCProvider.com under Policies and Protocols.
• UnitedHealthcare Outpatient Hospital Site of Care Review program policy, 2023-2026 editions.
• OptumRx Specialty Pharmacy Drug List and Specialty Drug Management List, current quarter.
• UHC Community Plan state-specific formularies (Medicaid managed care); CMS Part B and Part D coverage documents for UHC Medicare Advantage.
• Cordavis (CVS Health subsidiary) public statements on adalimumab biosimilar private-label distribution arrangements with UHC and other commercial payers, 2024-2025.
• AHIP specialty pharmacy guidance, current edition (cross-reference).
• BCBS Association biosimilar substitution policy framework (used as cross-reference for biosimilar mandate norms).

All sources are publicly available payer policy documents or paraphrased from trade-association educational materials. Payer policy URLs, fax numbers, and criteria change. Verify any operational detail (fax, portal URL, specific PA criteria) on UHCProvider.com or OptumRx’s provider portal before submission. The methodology by which we resolve source conflicts is described in the Methodology.

Related references